Cardiff Oncology (CRDF) vs Greenland Mines (GRML)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Cardiff Oncology (CRDF) has outperformed Greenland Mines (GRML) over the past year, losing 54.6% versus a loss of 83.3%. Cardiff Oncology is the larger company by market cap ($84.0 million vs $69.0 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRDF | GRML |
|---|---|---|
| Share price | $1.08 | $5.17 |
| Market cap | $84.02M | $69.00M |
| 1-day change | +1.89% | -12.07% |
| YTD return | -61.57% | -64.22% |
| 1-year return | -54.62% | -83.30% |
| 5-year return | -83.13% | — |
| EPS (TTM) | $-0.60 | $-9.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.31 | $37.00 |
| 52-week low | $0.76 | $2.82 |
| Distance from 52-week high | -67.37% | -86.03% |
| Analyst consensus | none | none |
| Avg. price target upside | +437.96% | +2027.66% |
| Average volume | 1.04M | 7.97M |
| Shares outstanding | 77.80M | 13.35M |
| Employees | 30 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRDF has outperformed GRML by 28.7 percentage points over the past year.
About Cardiff Oncology
CRDF stock →Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 30 employees
About Greenland Mines
GRML stock →Greenland Mines Ltd engages in the cell and gene therapy, and natural resources businesses. The company primarily explores palladium, gold, and platinum deposits.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5 employees
CRDF vs GRML FAQ
Which is bigger, Cardiff Oncology or Greenland Mines?
Cardiff Oncology (CRDF) is larger, with a market capitalization of $84.02M compared with $69.00M for Greenland Mines (GRML).
Which stock has performed better over the past year, CRDF or GRML?
CRDF returned -54.62% over the past 12 months, compared with -83.30% for GRML (price return, excluding dividends). Past performance does not predict future results.
Are Cardiff Oncology and Greenland Mines in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.